These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma. Goričar K; Kovač V; Dolžan V Pharmacogenomics; 2014 May; 15(7):941-50. PubMed ID: 24956248 [TBL] [Abstract][Full Text] [Related]
3. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V Cancer Epidemiol; 2015 Apr; 39(2):182-8. PubMed ID: 25592234 [TBL] [Abstract][Full Text] [Related]
4. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma. Ji WP; He NB Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792 [TBL] [Abstract][Full Text] [Related]
5. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073 [TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma. Sun Y; Wu Y; Li W; Kong Z; Zou X Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355 [TBL] [Abstract][Full Text] [Related]
7. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908 [TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317 [TBL] [Abstract][Full Text] [Related]
9. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma. Bai SB; Chen HX; Bao YX; Luo X; Zhong JJ Asian Pac J Cancer Prev; 2013; 14(6):3677-80. PubMed ID: 23886164 [TBL] [Abstract][Full Text] [Related]
10. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Yang LM; Li XH; Bao CF Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281 [TBL] [Abstract][Full Text] [Related]
11. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma. Zhang Q; Lv LY; Li BJ; Zhang J; Wei F Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354 [TBL] [Abstract][Full Text] [Related]
12. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680 [TBL] [Abstract][Full Text] [Related]
13. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy. Liu S; Yi Z; Ling M; Shi J; Qiu Y; Yang S Tumour Biol; 2014 Oct; 35(10):9897-904. PubMed ID: 24996541 [TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma. Shi ZW; Wang JL; Zhao N; Guan Y; He W Cancer Biomark; 2016 Jun; 17(2):249-57. PubMed ID: 27540978 [TBL] [Abstract][Full Text] [Related]
15. Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival. Varadi V; Bevier M; Grzybowska E; Johansson R; Enquist K; Henriksson R; Butkiewicz D; Pamula-Pilat J; Tecza K; Hemminki K; Lenner P; Försti A Breast Cancer Res Treat; 2011 Aug; 129(1):235-45. PubMed ID: 21455670 [TBL] [Abstract][Full Text] [Related]
16. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557 [TBL] [Abstract][Full Text] [Related]
17. Translesion synthesis mechanisms depend on the nature of DNA damage in UV-irradiated human cells. Quinet A; Martins DJ; Vessoni AT; Biard D; Sarasin A; Stary A; Menck CF Nucleic Acids Res; 2016 Jul; 44(12):5717-31. PubMed ID: 27095204 [TBL] [Abstract][Full Text] [Related]
18. Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy. Zhang SL; Mao NF; Sun JY; Shi ZC; Wang B; Sun YJ Asian Pac J Cancer Prev; 2012; 13(6):2705-9. PubMed ID: 22938445 [TBL] [Abstract][Full Text] [Related]
19. Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy. Li JZ; Tian ZQ; Jiang SN; Feng T Genet Mol Res; 2014 Apr; 13(2):3186-92. PubMed ID: 24841650 [TBL] [Abstract][Full Text] [Related]
20. COPS3 amplification and clinical outcome in osteosarcoma. Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]